Доброкачественная гиперплазия предстательной железы и ее осложнения в общемедицинской практике
Доброкачественная гиперплазия предстательной железы и ее осложнения в общемедицинской практике
Верткин А.Л., Лоран О.Б., Вовк Е.И., Зимин О.Н., Наумов А.В., Пак А.Д., Констанов Г.П., Кешоков Р.Х., Алексеев И.Д. Доброкачественная гиперплазия предстательной железы и ее осложнения в общемедицинской практике. Consilium Medicum. 2008; 10 (2): 14–21.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Лопаткин Н.А., Сивков А.В. Доброкачественная гиперплазия предстательной железы. М., 1999; 99–102.
2. Berry SJ, Coffey DS, Walsh PC et al. The development or human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–79.
3. Logie JW, Clifford GM et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction – Triumph: the role of general practice databases. Eur Urol 2001; 39 (Suppl 3): 42–7.
4. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–9.
5. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71.
6. Bartsch G, MЯller HR, Oberholzer M et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487–91.
7. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T et al. Alpha-Adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836–9.
8. Kyprianou N, Litvak JP, Borkowski A et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998; 159: 1810–5.
9. Montorsi F, Moncada I. Safety and tolerability of treatment for BPH. Eur Urol Sappl 2006; 5: 1005.
10. Barendrecht MM, Koopmans RP, de la JRosette et al. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: cardiovascular system. BJU Int 2005; 95: 19–28.
11. Djavan B, Chaple C, Milani S et al. State of the art on the efficacy and tolerability of alpha-adrenoreceptor antagonists in patients with low urinary tract symptoms suggestive of benign hyperplasia. Urology 2004; 64: 1081–8.
12. Buzelin JM, Fonteyne E, Kontturi M et al. Comparison of tamsulosin with alfuzosin in the treatment of patient with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign hyperplasia). The European Tamsulosin Study Group. Br J Urology 1997; 80: 597–605.
13. Koff W, Bertero E, Pinheiro G et al. A randomized, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia. Program and abstracts of the American Urological Association Annual Meeting. May 21–26. 2005. San Antonio, Texas. Abstract. 1643.
14. Hellstrom W, Smith W, Sikka C. Effects of alpha-blockers on ejaculatory function in normal subjects. Program and abstracts of the American Urological Association Annual Meeting. May 21–26. 2005. San Antonio, Texas. Abstract: 874.
15. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfusozin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double- blind, placebo-controlled stadies. BJU Int 2003; 92: 257–61.
16. Hofner K, Claes H, De Reijke TM et al. Tamsulosin 0,4 mg once daily: effect on sexual function in patints with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335–41.
17. Debruyne F, Barkin J, van Erps PV et al. Efficacy and safety of longterm treatment with the dual 5б-reductase inhibitir dutasteride in men with symptomatic benign hyperplasia. Eur Urol 2004; 46: 488–95.
18. Roehorborn CG, Lee M, Meehan A. PLESS Study Groupe. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003; 62: 894–9.
19. Controlled Clinical Trials the MTOPS. Elsevier science 2003; 24: 224–43.
20. Barkin J, Guimaraes M, Jacobi G et al., on behalf of the SMART-1 Investigator Groupe. Alfa-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5б-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461–6.
21. The 5th International Consultation on BHP Proceedings. 2001.
22. Marks LS. Preventing BPH Disease in asimptomatic Men at risk of progression. UAU. April/May 2006.
23. Marberger M et al. Eur Urol 2004; 45: 411–9.
2. Berry SJ, Coffey DS, Walsh PC et al. The development or human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–79.
3. Logie JW, Clifford GM et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction – Triumph: the role of general practice databases. Eur Urol 2001; 39 (Suppl 3): 42–7.
4. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–9.
5. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71.
6. Bartsch G, MЯller HR, Oberholzer M et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487–91.
7. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T et al. Alpha-Adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836–9.
8. Kyprianou N, Litvak JP, Borkowski A et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998; 159: 1810–5.
9. Montorsi F, Moncada I. Safety and tolerability of treatment for BPH. Eur Urol Sappl 2006; 5: 1005.
10. Barendrecht MM, Koopmans RP, de la JRosette et al. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: cardiovascular system. BJU Int 2005; 95: 19–28.
11. Djavan B, Chaple C, Milani S et al. State of the art on the efficacy and tolerability of alpha-adrenoreceptor antagonists in patients with low urinary tract symptoms suggestive of benign hyperplasia. Urology 2004; 64: 1081–8.
12. Buzelin JM, Fonteyne E, Kontturi M et al. Comparison of tamsulosin with alfuzosin in the treatment of patient with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign hyperplasia). The European Tamsulosin Study Group. Br J Urology 1997; 80: 597–605.
13. Koff W, Bertero E, Pinheiro G et al. A randomized, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia. Program and abstracts of the American Urological Association Annual Meeting. May 21–26. 2005. San Antonio, Texas. Abstract. 1643.
14. Hellstrom W, Smith W, Sikka C. Effects of alpha-blockers on ejaculatory function in normal subjects. Program and abstracts of the American Urological Association Annual Meeting. May 21–26. 2005. San Antonio, Texas. Abstract: 874.
15. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfusozin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double- blind, placebo-controlled stadies. BJU Int 2003; 92: 257–61.
16. Hofner K, Claes H, De Reijke TM et al. Tamsulosin 0,4 mg once daily: effect on sexual function in patints with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335–41.
17. Debruyne F, Barkin J, van Erps PV et al. Efficacy and safety of longterm treatment with the dual 5б-reductase inhibitir dutasteride in men with symptomatic benign hyperplasia. Eur Urol 2004; 46: 488–95.
18. Roehorborn CG, Lee M, Meehan A. PLESS Study Groupe. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003; 62: 894–9.
19. Controlled Clinical Trials the MTOPS. Elsevier science 2003; 24: 224–43.
20. Barkin J, Guimaraes M, Jacobi G et al., on behalf of the SMART-1 Investigator Groupe. Alfa-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5б-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461–6.
21. The 5th International Consultation on BHP Proceedings. 2001.
22. Marks LS. Preventing BPH Disease in asimptomatic Men at risk of progression. UAU. April/May 2006.
23. Marberger M et al. Eur Urol 2004; 45: 411–9.
Авторы
А.Л.Верткин, О.Б.Лоран, Е.И.Вовк, О.Н.Зимин, А.В.Наумов, А.Д.Пак, Г.П.Констанов, Р.Х.Кешоков, И.Д.Алексеев
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.